PPC may serve as a viable treatment option for patients with MAFLD along with significant liver inflammation (elevated ALT/AST level) and those at risk of significant fibrosis, particularly those with T2DM and/or cardiovascular metabolic risk factors. This evidence concerns the gene GPT and inflammation.